Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
biotech
boston blog main
boston top stories
editas medicine
gene editing
national top stories
san francisco blog main
san francisco top stories
boston
crispr
crispr therapeutics
crispr-cas9
enzyme
intellia therapeutics
agios therapeutics
allergan
base editing
branden moriarty
broad institute
cancer
cas13
clinical study
clinical trials
cynthia collins
data
david liu
disease
dna
drugs
editas
editor
editr
feng zhang
gag
genome editing
harvard university
hunter syndrome
ids
What
editing
4
×
gene
medicine
4
×
crispr
cas
editas
humans
therapeutics
trial
allergan
beam
benefit
blessing
bosley
cancer
cells
ceo
check
clinical
cusp
defect
depart
drive
edited
editor
experimental
fears
flag
founders
genetic
going
gotten
guardian
harvard
human
isn't
jump
katrine
known
lab
Language
Current search:
xconomy.com
×
medicine
×
editing
×
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M
